AU2022390803A1 - Compounds for use in treating gastric cancer - Google Patents

Compounds for use in treating gastric cancer Download PDF

Info

Publication number
AU2022390803A1
AU2022390803A1 AU2022390803A AU2022390803A AU2022390803A1 AU 2022390803 A1 AU2022390803 A1 AU 2022390803A1 AU 2022390803 A AU2022390803 A AU 2022390803A AU 2022390803 A AU2022390803 A AU 2022390803A AU 2022390803 A1 AU2022390803 A1 AU 2022390803A1
Authority
AU
Australia
Prior art keywords
formula
pharmaceutically acceptable
halo
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022390803A
Other languages
English (en)
Inventor
Vivek K. VISHNUDAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BPGbio Inc
Original Assignee
BPGbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BPGbio Inc filed Critical BPGbio Inc
Publication of AU2022390803A1 publication Critical patent/AU2022390803A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022390803A 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer Pending AU2022390803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280540P 2021-11-17 2021-11-17
US63/280,540 2021-11-17
PCT/US2022/050289 WO2023091590A1 (en) 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer

Publications (1)

Publication Number Publication Date
AU2022390803A1 true AU2022390803A1 (en) 2024-06-20

Family

ID=84887956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022390803A Pending AU2022390803A1 (en) 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer

Country Status (8)

Country Link
US (1) US20250017906A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433051A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543111A (cg-RX-API-DMAC7.html)
KR (1) KR20240149878A (cg-RX-API-DMAC7.html)
CN (1) CN118488837A (cg-RX-API-DMAC7.html)
AU (1) AU2022390803A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238430A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023091590A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138540A1 (en) * 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
US20240342138A1 (en) * 2023-04-13 2024-10-17 Bpgbio, Inc. Microtubule targeting agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210694A1 (en) * 2016-06-03 2017-12-07 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
BR112021004417A2 (pt) * 2018-09-10 2021-06-01 Berg Llc métodos para tratar câncer pela inibição de enzima e2 k de conjugação de ubiquitina (ube2k)
WO2021138540A1 (en) * 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer

Also Published As

Publication number Publication date
CA3238430A1 (en) 2023-05-25
US20250017906A1 (en) 2025-01-16
WO2023091590A1 (en) 2023-05-25
CN118488837A (zh) 2024-08-13
EP4433051A1 (en) 2024-09-25
JP2024543111A (ja) 2024-11-19
KR20240149878A (ko) 2024-10-15

Similar Documents

Publication Publication Date Title
AU2009279944B2 (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
TWI632911B (zh) 腫瘤溶解症候群之治療劑及預防劑
TWI810185B (zh) 一種ezh2抑制劑與btk抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2023091590A1 (en) Compounds for use in treating gastric cancer
TW201919612A (zh) 包含帕博西尼(palbociclib)及6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸的組合
KR20130079429A (ko) 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
JP2022527398A5 (cg-RX-API-DMAC7.html)
TW201306842A (zh) 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
JP2015512398A (ja) Pfkfb2阻害剤および抗癌治療法としての使用方法
WO2018233620A1 (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
CN103841976A (zh) Akt和mek抑制剂化合物的组合及其使用方法
JP2024069223A5 (cg-RX-API-DMAC7.html)
US6537991B1 (en) Method of treating a peripheral neuropathic pain
CA3205023A1 (en) Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
KR20220035143A (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
AU2014296145A1 (en) Compound and methods for treating long QT syndrome
JP2024523558A5 (cg-RX-API-DMAC7.html)
JP2024505515A5 (cg-RX-API-DMAC7.html)
AU2024229823B2 (en) Compositions and methods for making and using small molecules for the treatment of health conditions
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
WO2025202900A1 (en) Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
CN113966329B (zh) 作为pdl1检查点抑制剂的杂环免疫调节剂
US20240239760A1 (en) Pparg inverse agonists and uses thereof
JP2022532194A (ja) Pi3k阻害剤の結晶多形及びその製造方法
WO2024138160A1 (en) Pparg inverse agonists and uses thereof